Fair Value Calculator Fair Value Calculator
EN DE

Par Drugs and Chemicals Limited (PAR) Fair Value & Analysis

Healthcare · IN · Market cap ₹1.1B

PD Par Drugs and Chemicals Limited PAR · NSE
Price₹88.53
Fair Value₹219.53
Upside+148.0%
Quality58/100
Watch Par Drugs and Chemicals Limited for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹154.08 – ₹265.91

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price +3.3% over the past month.

Price vs Fair Value (12 months)

₹115.72 ₹76.70 Fair Value ₹219.53 Jul 2025 Jul 2026

12‑month range ₹76.70 – ₹115.72 · fair‑value band ₹154.08 – ₹265.91 · the ₹88.53 price screens below the ₹219.53 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Par Drugs and Chemicals Limited (PAR) currently trades at ₹88.53, while our model-based Fair Value estimate is ₹219.53 — implying the stock looks roughly 148.0% undervalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, Par Drugs and Chemicals Limited generated revenue of ₹1.0B at a net margin of 12.7%. Revenue declined 12.2% year over year. It earns a return on equity of 12.4%. The balance sheet holds a net cash position of ₹418M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹1.0B
Revenue growth (YoY) -12.2%
Net margin 12.7%
Return on equity 12.4%
Free cash flow ₹145M FY2026
P/E ratio 8.3
More key figures
Operating margin 2.6%
EPS (TTM) ₹10.65
EPS growth (YoY) -48.5%
Net cash ₹418M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

About the company

Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alusil, PARSIL-HT, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Par Drugs and Chemicals Limited reported revenue of ₹1.0B in FY2026 versus ₹746M in FY2022, a compound +8.6%/yr. Reported net income was ₹131M in FY2026, compounding +9.2%/yr from FY2022.

Revenue +8.6%/yr
FY22 ₹746M
FY23 ₹951M
FY24 ₹956M
FY25 ₹1.0B
FY26 ₹1.0B
Net income +9.2%/yr
FY22 ₹92.1M
FY23 ₹113M
FY24 ₹145M
FY25 ₹134M
FY26 ₹131M

Is PAR fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 1276 HK$57.85 HK$29.84 -48%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,786 ₹991.46 -44%
Zoetis Inc Z1TS34 R$25.93 R$19.70 -24%
Hansoh Pharmaceutical Group 3692 HK$29.30 HK$23.90 -18%
Divi's Laboratories Limited DIVISLAB ₹6,639 ₹1,281 -81%
Swedish Orphan Biovitrum AB SOBI kr 435.00 kr 285.77 -34%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Par Drugs and Chemicals Limited (PAR) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹219.53 versus a price of ₹88.53 — about +148% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PAR?
Our model-based fair value for Par Drugs and Chemicals Limited is ₹219.53 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹88.53.
What is the quality score of PAR?
Par Drugs and Chemicals Limited has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Par Drugs and Chemicals Limited (PAR)?
Par Drugs and Chemicals Limited reported trailing-twelve-month revenue of about ₹1.0B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of PAR?
The net profit margin of Par Drugs and Chemicals Limited is about 12.7%, meaning it keeps roughly 12.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.